The Efficacy Of Individual Of Bortezomib-based Regimens For Multiple Myeloma

Objective:To analyze 60 cases of patients with multiple myeloma in our hospital retrospectively. This paper focuses on the comparison of bortezomib in MM patients with individualized treatment programs than traditional. Through which we can compared between the two groups of overall response rate,overall survival and untoward effect to provide a reference for clinical treatment of MM patients in the future.Method:Select 60 hospitalized patients in our hospital hematology from 2010.1 to 2014.7 as research subjects,which divided into two groups were analyzed retrospctively. Group one: 20 cases of multiple myeloma patients received BDT(bortezomib, dexamethasone, thalidomide) therapy. 7 patients received 1.75mg(0.8-1.0mg / m2) bortezomib, on days 1,8. Then, 13 cases accepted 1.3mg / m2, the first 1,4,8,11 days; dexamethasone 5-15 mg / d, 1-4,8-11 first days; Continued treatment with thalidomide dose 100-150mg; The program is repeated again 21 days. And treatment with thalidomide maintenance therapy remains. If someone have discomfort during the treatment,it is necessary to adjust the dose or delay treatment. Group two: another 40 patients received conventional chemotherapy, including MPT(melphalan 4mg/ m2/d, prednisone 40mg/m2/d, both orally seven days; thalidomide 100 mg every night) and VADT(incristine 0.7mg, the first 1-4 days, doxorubicin 10 mg, the first 1-4 days, dexamethasone 40 mg, 1-4,9-12,17-20 first day; thalidomide 100-200 mg every night). Thalidomide maintenance therapy. Two programs were completed four courses.Results:BDT individualized treatment group, whose complete remission(CR) was 10%, a very good partial response(VGPR) is 50%, partial response(PR) was 20%, stable disease(SD) is 5%, the progress is 15 %;However,CR in conventional regimen group was 2.5%, VGPR was 37.5%, PR was 17.5%, SD 30% progressed to 12.5% ORR in both groups were 80% vs 57.5(P <0.05).To 2-year and 3-year OS,individual BDT group were higher than conventional therapy group, and the difference was statistically significant(P<0.05);In adverse reactions after treatment, the two groups of white blood cells, thrombocytopenia and infection, peripheral neuropathy had no differences.BDT group of individual had high incidence of herpes zoster, however, traditional treatment group had high incidence of weakness and cardiac toxicity.For patients with renal insufficiency and in patients with normal renal function therapeutically effective rate was 75% vs 83.3 %(P >0.05).And the renal function of individual BDT group were improving.Conclusion:BDT group individualized treatment MM is an effective and safe treatment programs.